DOSE DETERMINATION TRIAL FOR IMPLEMENTING EVIDENCE-BASEDBEHAVIORAL INTERVENTIONS

实施循证行为干预的剂量确定试验

基本信息

批准号：
10318539
负责人：
SETH C KALICHMAN
金额：
$ 59.44万
依托单位：
UNIVERSITY OF CONNECTICUT STORRS
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-01 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10318539
关键词：
Adherence Behavior Therapy Behavioral Behavioral Model Behavioral Research Benchmarking Caring Centers for Disease Control and Prevention (U.S.)Characteristics Clinical Clinical Trials Cost Effectiveness Analysis Counseling Development Dose Emotional Enrollment Evidence based intervention Glare Goals HIV Health Health Policy Health Services Individual Informal Social Control Intervention Intervention Trial Life Link Literature Masks Mental Health Modeling Monitor Outcome Participant Patients Persons Plasma Policies Policy Maker Population Poverty Randomized Reporting Research Resource Allocation Resources Subgroup Telephone Testing Time Viral Viral Load result antiretroviral therapy barrier to care base behavioral adherence behavioral clinical trial cost cost effectiveness design effective intervention evidence base flexibility follow up assessment implementation intervention implementation questions implementation science improved longitudinal analysis novel patient response patient subsets pragmatic implementation primary endpoint programs resource guides response scale up secondary outcome service providers skills social social factors social structure substance use theories therapy adherence therapy design viral rebound

项目摘要

The proposed research will conduct the first ever dose-determination trial of a behavioral intervention to improve engagement in HIV care, antiretroviral therapy (ART) adherence and HIV viral suppression. The trial is designed to inform the implementation of behavioral interventions, including several in CDC’s Compendium of Evidence-Based Interventions. Behavioral counseling has the flexibility and reach to overcome numerous challenges to HIV care, including social, emotional, and structural barriers. However, basic questions of how to best implement and scale-up interventions remain unanswered, such as “how much intervention is needed to achieve HIV suppression in subgroups of patients facing individual and social challenges?” There are currently no dose-determination trials in the HIV behavioral intervention literature to guide implementation decisions and health service policy. In the proposed research we specifically aim to: (a) determine the minimum effective dose of an evidence-based HIV treatment engagement and adherence intervention, (b) identify subgroups of patients requiring greater and fewer intervention resources to achieve and sustain viral suppression, and (c) the costs associated with intervention dose-response. Participants who are receiving ART and confirmed HIV unsuppressed (>200 copies/mL) will be randomized to either: (a) the dose determination condition of weekly evidence-based behavioral self-regulation counseling until achieving HIV suppression (<200 copies/mL), or (b) fixed dose 5-weekly sessions of evidence-based behavioral self-regulation counseling sessions. The dose determination condition adjusts to patient needs and determines the dose to achieve HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response. The trial is therefore designed to determine the number of behavioral counseling intervention sessions needed to achieve and sustain HIV suppression. Once viral suppressed, counseling in the dose-determination condition is suspended. In contrast, the fixed-dose condition is delivered in five prescribed sessions as disseminated by the CDC. Follow-up assessments commence for 12-months from baseline with the primary endpoint of 12-month blood plasma HIV viral load and secondary outcome of ART adherence. Response to counseling is defined by achieving viral suppression (<200 copies/mL) and non-response is defined by not achieving viral suppression (>200 copies/mL). Participants in both the dose-determination and fixed-session conditions who initially respond and rebound to unsuppressed viral load will receive additional counseling with redose-response monitored and analyzed. Longitudinal analyses will examine intervention dose for key patient subgroups and dose-response cost-effectiveness analyses to guide resource allocation and implementation decisions. This research is aimed at informing health policy makers and programmatic decisions regarding intervention implementation to increase the likelihood of sustained HIV suppression.

拟议的研究将进行有史以来第一次行为干预的剂量确定试验提高对艾滋病毒护理、抗逆转录病毒治疗 (ART) 依从性和艾滋病毒病毒抑制的参与度。试验旨在为行为干预措施的实施提供信息，包括 CDC 的多项干预措施循证干预纲要具有灵活性和覆盖面。克服艾滋病毒护理方面的众多挑战，包括社会、情感和结构障碍。如何最好地实施和扩大干预措施的基本问题仍未得到解答，例如“多少” 需要进行干预，以在面临个人和社会问题的亚组患者中实现艾滋病毒抑制目前还没有艾滋病毒行为干预的剂量确定试验在拟议的研究中，我们提供了实施决策和卫生服务政策的文献指南。具体目标是： (a) 确定基于证据的艾滋病毒治疗的最低有效剂量参与和干预依从性，(b) 确定需要更多和更少的患者亚组实现和维持病毒抑制的干预资源，以及 (c) 相关成本接受 ART 并确认 HIV 未受抑制的参与者（>200）拷贝数/mL）将被随机化为：（a）每周基于证据的剂量确定条件行为自我调节咨询，直至实现 HIV 抑制（<200 拷贝/mL），或 (b) 固定剂量每周 5 次基于证据的行为自我调节咨询课程。确定条件根据患者需求进行调整，并确定实现 HIV 抑制的剂量，与不根据患者反应进行调整的固定剂量条件相反，因此设计了该试验。确定实现和维持所需的行为咨询干预课程的数量 HIV 抑制。一旦病毒被抑制，剂量确定情况的咨询就会暂停。相比之下，固定剂量条件是按照 CDC 公布的五次规定疗程进行的。从基线开始为期 12 个月的随访评估，主要终点为 12 个月血浆 HIV 病毒载量和 ART 依从性的次要结果是。定义为实现病毒抑制（<200 拷贝/mL），无反应定义为未实现病毒抑制（>200 拷贝/mL）。剂量确定和固定疗程的参与者。最初对未抑制的病毒载量有反应并反弹的情况将接受额外的咨询监测和分析重剂量反应后，纵向分析将检查干预剂量。关键患者亚组和剂量反应成本效益分析，以指导资源分配和这项研究旨在为卫生决策者和规划者提供信息。有关实施干预措施的决定，以增加持续抑制艾滋病毒的可能性。